Tenet Healthcare (NYSE:THC) Stock Rating Reaffirmed as “Buy” by Truist Financial

by · The Markets Daily

Tenet Healthcare (NYSE:THC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Truist Financial in a note issued to investors on Tuesday, Benzinga reports. They presently have a $305.00 price target on the stock, up from their previous price target of $290.00. Truist Financial‘s target price suggests a potential upside of 11.40% from the company’s current price.

THC has been the topic of a number of other research reports. BMO Capital Markets assumed coverage on Tenet Healthcare in a report on Tuesday, September 22nd. They set a “market perform” rating and a $265.00 target price on the stock. Wall Street Zen raised Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 17th. Leerink Partners increased their price target on shares of Tenet Healthcare from $309.00 to $342.00 and gave the company an “outperform” rating in a research report on Monday. Guggenheim reduced their price objective on shares of Tenet Healthcare from $307.00 to $306.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Zacks Research cut shares of Tenet Healthcare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Eighteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $290.63.

Read Our Latest Stock Analysis on Tenet Healthcare

Tenet Healthcare Trading Up 1.8%

Shares of THC stock traded up $4.89 during trading hours on Tuesday, reaching $273.79. The company had a trading volume of 369,430 shares, compared to its average volume of 1,116,537. The company has a 50 day moving average of $264.61 and a 200 day moving average of $220.69. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. The firm has a market cap of $22.04 billion, a price-to-earnings ratio of 7.95, a P/E/G ratio of 1.02 and a beta of 1.20. Tenet Healthcare has a 1-year low of $157.58 and a 1-year high of $283.05.

Tenet Healthcare (NYSE:THC – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $4.68 by $1.96. The business had revenue of $6.28 billion during the quarter, compared to analysts’ expectations of $5.49 billion. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.70 earnings per share. On average, equities research analysts anticipate that Tenet Healthcare will post 21.98 EPS for the current year.

Insider Transactions at Tenet Healthcare

In related news, CEO Saumya Sutaria sold 50,000 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $278.71, for a total transaction of $13,935,500.00. Following the sale, the chief executive officer directly owned 483,564 shares in the company, valued at $134,774,122.44. This trade represents a 9.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Lisa Y. Foo sold 24,000 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $266.32, for a total transaction of $6,391,680.00. Following the completion of the sale, the executive vice president directly owned 8,053 shares in the company, valued at $2,144,674.96. This represents a 74.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 106,484 shares of company stock valued at $28,898,063. 0.97% of the stock is currently owned by insiders.

Institutional Trading of Tenet Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of THC. Manning & Napier Advisors LLC bought a new position in shares of Tenet Healthcare during the second quarter worth about $168,761,000. Arrowstreet Capital Limited Partnership raised its position in Tenet Healthcare by 57.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 671,700 shares of the company’s stock valued at $126,757,000 after buying an additional 244,901 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Tenet Healthcare in the 2nd quarter valued at approximately $106,342,000. Empowered Funds LLC lifted its stake in Tenet Healthcare by 22.1% in the 1st quarter. Empowered Funds LLC now owns 284,753 shares of the company’s stock valued at $53,736,000 after acquiring an additional 51,549 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in Tenet Healthcare by 11.8% during the 1st quarter. First Trust Advisors LP now owns 240,019 shares of the company’s stock worth $45,294,000 after acquiring an additional 25,263 shares during the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare News Summary

Here are the key news stories impacting Tenet Healthcare this week:

  • Positive Sentiment: KeyCorp raised its price target from $270 to $300 and maintained an “overweight” rating, implying approximately 9.9% potential upside from the referenced share price. KeyCorp recommendations
  • Positive Sentiment: Leerink Partners increased its target from $309 to $342 and assigned an “outperform” rating, the most optimistic target among the latest analyst revisions, with roughly 25.3% implied upside. Leerink Partners recommendations
  • Positive Sentiment: Royal Bank of Canada raised its target from $283 to $304 and kept an “outperform” rating, reflecting expectations for further gains. RBC recommendations
  • Positive Sentiment: Wells Fargo lifted its target from $281 to $321 and maintained an “overweight” rating, citing a favorable outlook for Tenet’s earnings trajectory. Wells Fargo recommendations
  • Positive Sentiment: Tenet reportedly raised its 2026 EBITDA outlook following third-quarter results, while its earnings call pointed to stronger growth ahead. The improved outlook supports the recent upward revisions in analyst targets. Tenet Healthcare EBITDA outlook
  • Negative Sentiment: Guggenheim trimmed its price target for Tenet Healthcare, providing a counterpoint to the broader wave of bullish revisions and signaling that some analysts remain cautious about valuation or execution risks. Guggenheim price target update

Tenet Healthcare Company Profile

(Get Free Report)

Tenet Healthcare Corp. (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, Texas. Through its hospital operations and outpatient platforms, the company provides a range of medical services to patients across the United States.

Tenet operates acute care and specialty hospitals, ambulatory surgery centers, imaging facilities and other outpatient care sites. Its United Surgical Partners International subsidiary is a major provider of ambulatory surgery services and partners with physicians and health systems.

Further Reading